| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H37N5O5S |
| Molecular Weight | 531.667 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC1=CC=C(C=C1C2=NC3=C(N(CC)C=C3CCC)C(=O)N2)S(=O)(=O)N4CCN(CCO)CC4
InChI
InChIKey=MIJFNYMSCFYZNY-UHFFFAOYSA-N
InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)
| Molecular Formula | C26H37N5O5S |
| Molecular Weight | 531.667 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
The inhibition of cyclic nucleotide Phosphodiesterase type 5 (PDE5) has been clinically validated as an effective treatment for erectile dysfunction. One of them is mirodenafil (formerly known as SK-3530) approved only in Korea. This drug was developed by SK Chemicals and marketed under the trade name Mvix.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
One tablet (Mirodenafil 50mg or 100mg) recommended dosing frequency is once per day. Taken orally approximately 60 minutes before sexual activity. Sexual stimulation is required for a response to treatment.
Route of Administration:
Oral
